(Q38790630)

6 September 2017

Targeting the mTOR Pathway in Leukemia (English)

1 reference

6 September 2017

1 reference

Shira Dinner

1

1 reference

PubMed ID

27018341

6 September 2017

Leonidas C Platanias

series ordinal

2

1 reference

6 September 2017

28 March 2016

1 reference

Journal of Cellular Biochemistry

6 September 2017

1 reference

6 September 2017

117

1 reference

6 September 2017

8

1 reference

6 September 2017

1745-1752

1 reference

PI3K/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor

6 September 2017

1 reference

The pan-class I phosphatidyl-inositol-3 kinase inhibitor NVP-BKM120 demonstrates anti-leukemic activity in acute myeloid leukemia

21 January 2018

1 reference

Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors

21 January 2018

1 reference

Autophagy is a survival mechanism of acute myelogenous leukemia precursors during dual mTORC2/mTORC1 targeting

21 January 2018

1 reference

Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells

21 January 2018

1 reference

mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells

21 January 2018

1 reference

The evolution of the TOR pathway and its role in cancer

21 January 2018

1 reference

21 January 2018

The two TORCs and Akt.

1 reference

The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model

21 January 2018

1 reference

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development

21 January 2018

1 reference

The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies

21 January 2018

1 reference

A potential therapeutic strategy for chronic lymphocytic leukemia by combining Idelalisib and GS-9973, a novel spleen tyrosine kinase (Syk) inhibitor

21 January 2018

1 reference

Lack of antileukemic activity of rapamycin in elderly patients with acute myeloid leukemia evolving from a myelodysplastic syndrome

21 January 2018

1 reference

Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells

21 January 2018

1 reference

Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia

21 January 2018

1 reference

Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.

21 January 2018

1 reference

A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia

21 January 2018

1 reference

MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies

21 January 2018

1 reference

Dual targeting of acute myeloid leukemia progenitors by catalytic mTOR inhibition and blockade of the p110α subunit of PI3 kinase

21 January 2018

1 reference

Inhibition of PI3K/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2.

21 January 2018

1 reference

Akt inhibitor MK2206 selectively targets CLL B-cell receptor induced cytokines, mobilizes lymphocytes and synergizes with bendamustine to induce CLL apoptosis

21 January 2018

1 reference

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells

21 January 2018

1 reference

Disruption of autophagy by the histone deacetylase inhibitor MGCD0103 and its therapeutic implication in B-cell chronic lymphocytic leukemia.

21 January 2018

1 reference

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

21 January 2018

1 reference

An overview of the mTOR pathway as a target in cancer therapy.

21 January 2018

1 reference

CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia

21 January 2018

1 reference

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells.

21 January 2018

1 reference

Targeting NOTCH1 in T-ALL: Starving the dragon

21 January 2018

1 reference

Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia

21 January 2018

1 reference

Hypersensitivity of Ph-positive lymphoid cell lines to rapamycin: Possible clinical application of mTOR inhibitor

21 January 2018

1 reference

The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia

21 January 2018

1 reference

Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells

21 January 2018

1 reference

CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

21 January 2018

1 reference

Rapamycin restores p14, p15 and p57 expression and inhibits the mTOR/p70S6K pathway in acute lymphoblastic leukemia cells

21 January 2018

1 reference

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

21 January 2018

1 reference

Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

21 January 2018

1 reference

High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling

21 January 2018

1 reference

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

21 January 2018

1 reference

Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation

21 January 2018

1 reference

Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia

21 January 2018

1 reference

Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells

21 January 2018

1 reference

A phase I study of the mammalian target of rapamycin inhibitor sirolimus and MEC chemotherapy in relapsed and refractory acute myelogenous leukemia.

21 January 2018

1 reference

BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance

21 January 2018

1 reference

Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.

21 January 2018

1 reference

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies

21 January 2018

1 reference

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

21 January 2018

1 reference

Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.

21 January 2018

1 reference

Selective targeting of the mTORC1/2 protein kinase complexes leads to antileukemic effects in vitro and in vivo.

21 January 2018

1 reference

Evaluation of antileukaemic effects of rapamycin in patients with imatinib-resistant chronic myeloid leukaemia.

21 January 2018

1 reference

PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability

21 January 2018

1 reference

Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia

21 January 2018

1 reference

Constitutive phosphoinositide 3-kinase/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients.

21 January 2018

1 reference

Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia

21 January 2018

1 reference

Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

21 January 2018

1 reference

The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL

21 January 2018

1 reference

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.

21 January 2018

1 reference

Toward a NOTCH1/FBXW7/RAS/PTEN-based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study.

21 January 2018

1 reference

Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells

21 January 2018

1 reference

Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia

21 January 2018

1 reference

TOR signaling in growth and metabolism

21 January 2018

1 reference

Combined inhibition of the phosphoinosityl-3-kinase (PI3Kinase) P110δ subunit and mitogen-extracellular activated protein kinase (MEKinase) shows synergistic cytotoxicity against human acute myeloid leukemia progenitors.

21 January 2018

1 reference

Survival of acute myeloid leukemia cells requires PI3 kinase activation

21 January 2018

1 reference

Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells

21 January 2018

1 reference

FAK mediates a compensatory survival signal parallel to PI3K-AKT in PTEN-null T-ALL cells.

21 January 2018

1 reference

Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment

21 January 2018

1 reference

Evaluation of apoptosis induction by concomitant inhibition of MEK, mTOR, and Bcl-2 in human acute myelogenous leukemia cells

21 January 2018

1 reference

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

21 January 2018

1 reference

Activation of mTORC2 by association with the ribosome

21 January 2018

1 reference

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCB.25559

1 reference

6 September 2017

1 reference

PubMed ID

27018341